Avacta Therapeutics announces agreement to sell Coris Bioconcept SRL
LONDON: Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announced the sale of Coris Bioconcept SRL to 3B BlackBio Dx Ltd for an upfront cash consideration of £2.15 million (including net cash & customary…